Arthur Stril

Chief Business Officer • Cellectis

Arthur Stril serves as Cellectis’ Chief Business Officer since September 2020, overseeing business development, strategy, and program management. Arthur joined Cellectis in July 2018 as Vice President, Corporate Development. Arthur began his career at the European Commission’s Directorate-General for Competition, controlling global pharmaceutical mergers such as the Novartis/GSK and Sanofi/Boehringer Ingelheim asset swaps, Pfizer’s acquisition of Hospira, and Teva’s acquisition of Actavis Generics. He later became Head of the Hospital Financing unit at the French Ministry of Health, where he led a team responsible for the €80bn hospital budget. Arthur graduated from the École Normale Supérieure, Paris & Cambridge University, and holds a diploma in Immunotherapy from the Université Paris-Descartes. Arthur is also a member of the French Corps des Mines.

Also Speaking

Ramin Baghirzade

Senior Director, Gene Therapy  • Charles River

David Barrett

Chief Executive Officer • American Society for Gene and Cell Therapy (ASGCT)

Amy DuRoss

President, Cell and Gene Therapy • CSafe

Also Speaking


Post-Event Report

Download the post-event report for Advanced Therapies Week 2023.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.